An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

MYRBETRIQ®

Drug Information Related Patent
Hold Company
Astellas Pharma US, Inc
Learn More
Dosage and Administration
TABLET, EXTENDED RELEASE;ORAL
Specification
25MG; 50MG
Indication
MYRBETRIQ® is indicated for adults with overactive bladder (OAB) and children with neurogenic detrusor overactivity (NDO).
Use
Instructions for Use
API
MIRABEGRON
API Structure
We Supply
MIRABEGRON
Note:

USP/In-house Standard/CP
Facility GMP
USMF/DMF/WC/ASMF/KDMF

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
108427802029/9/28
10842780*PED2030/3/28
117074512029/9/28
11707451*PED2030/3/28
73421172023/11/4
7342117*PED2024/5/4
79820492023/11/4
7982049*PED2024/5/4
87723152028/10/30
8772315*PED2029/4/30
88354742023/11/4
8835474*PED2024/5/4
RE448722023/11/4
RE44872*PED2024/5/4
API Patent
Patent NoExpiration Date
73421172023/11/4
7342117*PED2024/5/4
79820492023/11/4
7982049*PED2024/5/4
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top